View Financial HealthSymBio Pharmaceuticals 配当と自社株買い配当金 基準チェック /06SymBio Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回り-18.9%バイバック利回り総株主利回り-18.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 07SymBio Pharmaceuticals Limited to Report Q2, 2026 Results on Jul 30, 2026SymBio Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jul 30, 2026お知らせ • May 07SymBio Pharmaceuticals Limited to Report Q1, 2026 Results on May 07, 2026SymBio Pharmaceuticals Limited announced that they will report Q1, 2026 results on May 07, 2026お知らせ • Feb 05SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2026SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2026.お知らせ • Dec 27SymBio Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Feb 05, 2026SymBio Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Feb 05, 2026お知らせ • Oct 07SymBio Pharmaceuticals Limited to Report Q3, 2025 Results on Oct 30, 2025SymBio Pharmaceuticals Limited announced that they will report Q3, 2025 results on Oct 30, 2025お知らせ • Aug 14SymBio Pharmaceuticals Limited announced that it has received ¥1.3033 billion in funding from Evolution Capital Management LLCOn August 12, 2025. SymBio Pharmaceuticals Limited announced that it has closed the transaction.お知らせ • Jul 24SymBio Pharmaceuticals Limited announced that it expects to receive ¥1.3033 billion in funding from Evolution Capital Management LLCSymBio Pharmaceuticals Limited announced a private placement of 200,000 units 65th stock acquisition rights at an issue price of ¥8 per unit for gross proceeds of ¥1,600,000, 200,000 units 66th stock acquisition rights at an issue price of ¥7 per unit for gross proceeds of ¥1,400,000, 100,000 units 67th stock acquisition rights at an issue price of ¥3 per unit for gross proceeds of ¥300,000 on July 22, 2025. The total Total number of stock acquisition rights 500,000 units and total aggregate gross proceeds being ¥3,300,000. The potential shares resulting from the issuance of stock acquisition rights for 65th stock acquisition rights are 20,000,000 shares, 67th stock acquisition rights for 100,000 shares,67th Stock Acquisition Rights for 10,000,000 shares. The minimum exercise price is ¥84 for each issue and The initial exercise price is ¥168. The exercise period for all the stock acquisition rights is From August 13, 2025 to May 15, 2028. The transaction includes participation from EVO FUND. The transaction is expected to close on August 12, 2025. The company will also issue Zero Coupon Series 1 Unsecured Straight Bonds due October 26, 2026 for proceeds of ¥1,300,000,000. The transaction includes participation from EVO FUND. The bonds have zero interest rate and matures on October 26, 2026 and will pay Late fee: 20.0% per annum. The offering is expected to close on August 26, 2025お知らせ • Jul 02SymBio Pharmaceuticals Limited to Report Q2, 2025 Results on Jul 31, 2025SymBio Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jul 31, 2025お知らせ • Apr 11SymBio Pharmaceuticals Limited announced that it has received ¥1.8 billion in funding from Cantor Fitzgerald EuropeOn April 11, 2025, SymBio Pharmaceuticals Limited closed the transaction.お知らせ • Apr 04SymBio Pharmaceuticals Limited to Report Q1, 2025 Results on May 08, 2025SymBio Pharmaceuticals Limited announced that they will report Q1, 2025 results on May 08, 2025お知らせ • Feb 06SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 25, 2025SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 25, 2025.お知らせ • Oct 06SymBio Pharmaceuticals Limited to Report Q3, 2024 Results on Oct 31, 2024SymBio Pharmaceuticals Limited announced that they will report Q3, 2024 results on Oct 31, 2024お知らせ • Jun 28SymBio Pharmaceuticals Limited to Report Q2, 2024 Results on Aug 01, 2024SymBio Pharmaceuticals Limited announced that they will report Q2, 2024 results on Aug 01, 2024お知らせ • Mar 20SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLCOn March 18, 2024, SymBio Pharmaceuticals Limited closed the transaction. The company amended the terms of the transaction and issued 1,350,000 common shares at an issue price of ¥190 per share for the gross proceeds of ¥256,500,000.お知らせ • Feb 08+ 1 more updateSymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024.お知らせ • Jan 19SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024SymBio Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Feb 08, 2024お知らせ • Sep 28SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023SymBio Pharmaceuticals Limited announced that they will report Q3, 2023 results on Nov 14, 2023お知らせ • Jun 28SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023SymBio Pharmaceuticals Limited announced that they will report Q2, 2023 results on Aug 03, 2023お知らせ • Jan 13SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023SymBio Pharmaceuticals Limited announced that they will report fiscal year 2022 results on Feb 09, 2023決済の安定と成長配当データの取得安定した配当: SYMQ.Yの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SYMQ.Yの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場SymBio Pharmaceuticals 配当利回り対市場SYMQ.Y 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SYMQ.Y)n/a市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (SYMQ.Y) (最長3年)n/a注目すべき配当: SYMQ.Yは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SYMQ.Yは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SYMQ.Yの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SYMQ.Yが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/29 22:39終値2026/01/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SymBio Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Nathaniel CallowayEdison Investment ResearchKiyokazu YamazakiIchiyoshi Research Institute Inc.
お知らせ • Jul 07SymBio Pharmaceuticals Limited to Report Q2, 2026 Results on Jul 30, 2026SymBio Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jul 30, 2026
お知らせ • May 07SymBio Pharmaceuticals Limited to Report Q1, 2026 Results on May 07, 2026SymBio Pharmaceuticals Limited announced that they will report Q1, 2026 results on May 07, 2026
お知らせ • Feb 05SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2026SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2026.
お知らせ • Dec 27SymBio Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Feb 05, 2026SymBio Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Feb 05, 2026
お知らせ • Oct 07SymBio Pharmaceuticals Limited to Report Q3, 2025 Results on Oct 30, 2025SymBio Pharmaceuticals Limited announced that they will report Q3, 2025 results on Oct 30, 2025
お知らせ • Aug 14SymBio Pharmaceuticals Limited announced that it has received ¥1.3033 billion in funding from Evolution Capital Management LLCOn August 12, 2025. SymBio Pharmaceuticals Limited announced that it has closed the transaction.
お知らせ • Jul 24SymBio Pharmaceuticals Limited announced that it expects to receive ¥1.3033 billion in funding from Evolution Capital Management LLCSymBio Pharmaceuticals Limited announced a private placement of 200,000 units 65th stock acquisition rights at an issue price of ¥8 per unit for gross proceeds of ¥1,600,000, 200,000 units 66th stock acquisition rights at an issue price of ¥7 per unit for gross proceeds of ¥1,400,000, 100,000 units 67th stock acquisition rights at an issue price of ¥3 per unit for gross proceeds of ¥300,000 on July 22, 2025. The total Total number of stock acquisition rights 500,000 units and total aggregate gross proceeds being ¥3,300,000. The potential shares resulting from the issuance of stock acquisition rights for 65th stock acquisition rights are 20,000,000 shares, 67th stock acquisition rights for 100,000 shares,67th Stock Acquisition Rights for 10,000,000 shares. The minimum exercise price is ¥84 for each issue and The initial exercise price is ¥168. The exercise period for all the stock acquisition rights is From August 13, 2025 to May 15, 2028. The transaction includes participation from EVO FUND. The transaction is expected to close on August 12, 2025. The company will also issue Zero Coupon Series 1 Unsecured Straight Bonds due October 26, 2026 for proceeds of ¥1,300,000,000. The transaction includes participation from EVO FUND. The bonds have zero interest rate and matures on October 26, 2026 and will pay Late fee: 20.0% per annum. The offering is expected to close on August 26, 2025
お知らせ • Jul 02SymBio Pharmaceuticals Limited to Report Q2, 2025 Results on Jul 31, 2025SymBio Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jul 31, 2025
お知らせ • Apr 11SymBio Pharmaceuticals Limited announced that it has received ¥1.8 billion in funding from Cantor Fitzgerald EuropeOn April 11, 2025, SymBio Pharmaceuticals Limited closed the transaction.
お知らせ • Apr 04SymBio Pharmaceuticals Limited to Report Q1, 2025 Results on May 08, 2025SymBio Pharmaceuticals Limited announced that they will report Q1, 2025 results on May 08, 2025
お知らせ • Feb 06SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 25, 2025SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 25, 2025.
お知らせ • Oct 06SymBio Pharmaceuticals Limited to Report Q3, 2024 Results on Oct 31, 2024SymBio Pharmaceuticals Limited announced that they will report Q3, 2024 results on Oct 31, 2024
お知らせ • Jun 28SymBio Pharmaceuticals Limited to Report Q2, 2024 Results on Aug 01, 2024SymBio Pharmaceuticals Limited announced that they will report Q2, 2024 results on Aug 01, 2024
お知らせ • Mar 20SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLCOn March 18, 2024, SymBio Pharmaceuticals Limited closed the transaction. The company amended the terms of the transaction and issued 1,350,000 common shares at an issue price of ¥190 per share for the gross proceeds of ¥256,500,000.
お知らせ • Feb 08+ 1 more updateSymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024.
お知らせ • Jan 19SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024SymBio Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Feb 08, 2024
お知らせ • Sep 28SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023SymBio Pharmaceuticals Limited announced that they will report Q3, 2023 results on Nov 14, 2023
お知らせ • Jun 28SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023SymBio Pharmaceuticals Limited announced that they will report Q2, 2023 results on Aug 03, 2023
お知らせ • Jan 13SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023SymBio Pharmaceuticals Limited announced that they will report fiscal year 2022 results on Feb 09, 2023